The ACE Axcel Clinical Chemistry System is an automated, discrete, bench-top, random access analyzer that is intended for in vitro diagnostic use in the quantitative determination of constituents in blood and other fluids.

ACE Hemoglobin A1c (HbA1c) Reagent is intended for the quantitative determination of hemoglobin A1c (µmol/L) and total hemoglobin (g/dL) in human EDTA whole blood for the calculation of percent hemoglobin A1c using the ACE Axcel Clinical Chemistry System. The test is intended for use in clinical laboratories or physician office laboratories to monitor long term blood glucose control in individuals with diabetes mellitus. For in vitro diagnostic use only.

The ACE CEDIA T Uptake homogenous enzyme immunoassay is intended for the quantitative determination of unoccupied binding sites of thyroxine-binding proteins in serum using the ACE Axcel Clinical Chemistry System. Measurements of triiodothyronine uptake are used in the diagnosis and treatment of thyroid disorders. This test is intended for use in clinical laboratories or physician office laboratories. For in vitro diagnostic use only.

The ACE T4 Reagent is intended for the quantitative determination of total thyroxine (T4) concentration in serum using the ACE Axcel Clinical Chemistry System. Total thyroxine measurements are used in the diagnosis and treatment of thyroid diseases. This test is intended for use in clinical laboratories or physician office laboratories. For in vitro diagnostic use only.

The ACE Ferritin Reagent is intended for the quantitative determination of ferritin concentration in serum using the ACE Axcel Clinical Chemistry System. Measurements of ferritin aid in the diagnosis of diseases affecting iron metabolism, such as hemochromatosis (iron overload) and iron deficiency anemia. This test is intended for use in clinical laboratories or physician office laboratories. For in vitro diagnostic use only.

Device Description

The ACE Axcel Clinical Chemistry System consists of two major components, the chemistry instrument and an integrated Panel PC. The instrument accepts the physical patient samples, performs the appropriate optical or potentiometric measurements on those samples and communicates that data to an integral Panel PC. The Panel PC uses keyboard or touch screen input to manually enter a variety of data, control and accept data from the instrument, manage and maintain system information and generate reports relative to patient status and instrument performance. The Panel PC also allows remote download of patient requisitions and upload of patient results via a standard interface.

Prior to the ACE Hemoglobin A1c (HbA1c) Reagent assay, whole blood samples require a pretreatment step, which is done on-board the analyzer. The red blood cells in the sample are lysed by the Hemoglobin Denaturant and the hemoglobin chains are hydrolyzed. For determination of HbA1c, a latex agglutination inhibition assay is used. In the absence of HbA1c in the sample, the agglutinator (synthetic polymer containing the immunoreactive portion of HbA1c) in the HbA1c Agglutinator Reagent and the antibody-coated microparticles in the HbA1c Antibody Reagent will agglutinate. The presence of HbA1c in the sample competes for the antibody binding sites and inhibits agglutination. The increase in absorbance, monitored monochromatically at 592 nm, is inversely proportional to the HbA1c present in the sample. For the determination of total hemoglobin, all hemoglobin derivatives in the sample are converted to alkaline hematin. The reaction produces a green colored solution, which is measured bichromatically at 573 nm/692 nm. The intensity of color produced is directly proportional to the total hemoglobin concentration in the sample. The concentrations of both HbA1c and total hemoglobin are measured, the ratio is calculated and the result reported as percent HbA1c.

The CEDIA T Uptake assay uses recombinant DNA technology to produce a unique homogeneous enzyme immunoassay system. The assay is based the bacterial enzyme β-galactosidase, which has been genetically engineered into two inactive fragments. These fragments spontaneously re-associate to form fully active enzyme which, in the assay format, cleaves a substrate, generating a color change that can be measured spectrophotometrically. In the assay, enzyme donor thyroxine conjugate binds directly to the unoccupied thyroxine-binding sites in the sample, preventing the spontaneous re-association of the enzyme fragments to form the active enzyme. Thus, thyroxine-binding proteins regulate the amount of β-galactosidase formed from the reassembly of the remaining donor and enzyme acceptor as monitored by the hydrolysis of the substrate o-nitrophenyl-β-galactopyranoside.

The ACE T4 Assay is a homogeneous enzyme immunoassay using ready-to-use liquid ACE T4 Reagent. The assay uses 8-anilino-1-naphthalene sulfonic acid (ANS) to dissociate thyroxine from the plasma binding proteins. Using specific antibodies to thyroxine, this assay is based on the competition of glucose-6-phosphate dehydrogenase (G6PD) labeled thyroxine and the dissociated thyroxine in the sample for a fixed amount of specific antibody binding sites. In the absence of thyroxine from the sample, the thyroxine labeled G6PD in the second reagent is bound by the specific antibody in the first reagent, inhibiting the enzyme's activity. The enzyme G6PD catalyzes the oxidation of glucose-6-phosphate (G6P) with nicotinamide adenine dinucleotide (NAD+) to form 6-phosphogluconate and reduced nicotinamide adenine dinucleotide (NADH). NADH strongly absorbs at 340 nm whereas NAD+ does not. The rate of conversion, determined by measuring the increase in absorbance bichromatically at 340 nm/505 nm during a fixed time interval, is directly proportional to the amount of thyroxine in the sample. The concentration of thyroxine is determined automatically by the ACE Clinical Chemistry System using a logarithmic calibration curve established with calibrators, which are provided separately.

In the Ferritin Assay, serum ferritin, in the presence of anti-ferritin conjugated latex micorparticles, and a buffer promoting aggregation, initiates an antigen-antibody reaction, resulting in the agglutination of the latex microparticles. The agglutination is detected turbidometrically by an absorbance change measured at a wavelength of 592 nm. The magnitude of the absorbance change is proportional to the ferritin concentration in the sample.

AI/ML Overview

The provided text is a 510(k) summary for the Alfa Wassermann Diagnostic Technologies ACE Axcel Clinical Chemistry System and several associated reagents. It describes the devices, their intended uses, and technological characteristics. However, the document does not contain any information about acceptance criteria or a study that proves the device meets specific acceptance criteria.

The content of the document focuses on:

Identification of the device and reagents: Trade names, classifications, common names, and product codes.
Predicate devices: Listing the previously approved systems and reagents used for comparison in the 510(k) submission.
Device descriptions: Detailed explanations of the ACE Axcel Clinical Chemistry System's functionality and the biochemical principles of each reagent (HbA1c, CEDIA T Uptake, T4, Ferritin).
Intended Use/Indications for Use: What each device/reagent is designed to measure and for what clinical purpose.
Technological Characteristics: Specifications of the analyzer (throughput, reagent capacity, cooling, sample handling, optical system).
Regulatory approval notice: A letter from the FDA indicating substantial equivalence.

Therefore, I cannot provide a table of acceptance criteria or details of a study proving the device meets those criteria from the provided text. The requested information about sample sizes, data provenance, expert qualifications, ground truth, MRMC studies, or standalone performance studies is not present in this document.

Summary

{0}------------------------------------------------

1C//3437

510(k) SUMMARY

AUG

510(k) Owner:	Alfa Wassermann Diagnostic Technologies, LLC4 Henderson DriveWest Caldwell, NJ 07006
Contact:	Hyman Katz, Ph.D.Phone: 973-852-0158Fax: 973-852-0237
Date SummaryPrepared:	November 18, 2011
Device:	Trade Name:	ACE Axcel Clinical Chemistry System
	Classification:	Class 1
	Common/Classification Name:	Analyzer, Chemistry (Photometric,Discrete), For Clinical Use(21 C.F.R. § 862.2610)Product Code JJE
	Trade Name:	ACE Hemoglobin A1c (HbA1c) Reagent
	Classification:	Class 2
	Common/Classification Name:	Assay, Glycosylated Hemoglobin(21 C.F.R. § 864.7470)Product Code LCP
	Trade Name:	ACE CEDIA T Uptake Reagent
	Classification:	Class 2
	Common/Classification Name:	Radioassay, Triiodothyronine Uptake(21 C.F.R. § 862.1715)Product Code KHQ
	Trade Name:	ACE T4 Reagent
	Classification:	Class 2
	Common/Classification Name:	Enzyme Immunoassay, Non-Radiolabeled,Total Thyroxine(21 C.F.R. § 862.1700)Product Code KLI
	Trade Name:	ACE Ferritin Reagent
	Classification:	Class 2
	Common/Classification Name:	Ferritin, Antigen, Antiserum, Control(21 C.F.R. § 866.5340)Product Code DBF
PredicateDevices:	Manufacturer for analyzer/reagent system predicate:Alfa Wassermann ACE Clinical Chemistry System (K931786)ACE Reagents (K063306, K981375, K981377 and K050944)
DeviceDescriptions:	The ACE Axcel Clinical Chemistry System consists of two major components,the chemistry instrument and an integrated Panel PC. The instrument acceptsthe physical patient samples, performs the appropriate optical or potentiometricmeasurements on those samples and communicates that data to an integralPanel PC. The Panel PC uses keyboard or touch screen input to manually entera variety of data, control and accept data from the instrument, manage andmaintain system information and generate reports relative to patient status andinstrument performance. The Panel PC also allows remote download of patientrequisitions and upload of patient results via a standard interface.Prior to the ACE Hemoglobin A1c (HbA1c) Reagent assay, whole bloodsamples require a pretreatment step, which is done on-board the analyzer. Thered blood cells in the sample are lysed by the Hemoglobin Denaturant and thehemoglobin chains are hydrolyzed. For determination of HbA1c, a latexagglutination inhibition assay is used. In the absence of HbA1c in the sample,the agglutinator (synthetic polymer containing the immunoreactive portion ofHbA1c) in the HbA1c Agglutinator Reagent and the antibody-coatedmicroparticles in the HbA1c Antibody Reagent will agglutinate. The presenceof HbA1c in the sample competes for the antibody binding sites and inhibitsagglutination. The increase in absorbance, monitored monochromatically at592 nm, is inversely proportional to the HbA1c present in the sample. For thedetermination of total hemoglobin, all hemoglobin derivatives in the sampleare converted to alkaline hematin. The reaction produces a green coloredsolution, which is measured bichromatically at 573 nm/692 nm. The intensityof color produced is directly proportional to the total hemoglobin concentrationin the sample. The concentrations of both HbA1c and total hemoglobin aremeasured, the ratio is calculated and the result reported as percent HbA1c.The CEDIA T Uptake assay uses recombinant DNA technology to produce aunique homogeneous enzyme immunoassay system. The assay is based thebacterial enzyme β-galactosidase, which has been genetically engineered intotwo inactive fragments. These fragments spontaneously re-associate to formfully active enzyme which, in the assay format, cleaves a substrate, generatinga color change that can be measured spectrophotometrically. In the assay,enzyme donor thyroxine conjugate binds directly to the unoccupied thyroxine-binding sites in the sample, preventing the spontaneous re-association of the
	enzyme fragments to form the active enzyme. Thus, thyroxine-binding proteins
	regulate the amount of β-galactosidase formed from the reassembly of the
	remaining donor and enzyme acceptor as monitored by the hydrolysis of the
	substrate o-nitrophenyl-β-galactopyranoside.

	The ACE T4 Assay is a homogeneous enzyme immunoassay using ready-to-use liquid ACE T4 Reagent. The assay uses 8-anilino-1-naphthalene sulfonic acid (ANS) to dissociate thyroxine from the plasma binding proteins. Using specific antibodies to thyroxine, this assay is based on the competition of glucose-6-phosphate dehydrogenase (G6PD) labeled thyroxine and the dissociated thyroxine in the sample for a fixed amount of specific antibody binding sites. In the absence of thyroxine from the sample, the thyroxine labeled G6PD in the second reagent is bound by the specific antibody in the first reagent, inhibiting the enzyme's activity. The enzyme G6PD catalyzes the oxidation of glucose-6-phosphate (G6P) with nicotinamide adenine dinucleotide (NAD+) to form 6-phosphogluconate and reduced nicotinamide adenine dinucleotide (NADH). NADH strongly absorbs at 340 nm whereas NAD+ does not. The rate of conversion, determined by measuring the increase in absorbance bichromatically at 340 nm/505 nm during a fixed time interval, is directly proportional to the amount of thyroxine in the sample. The concentration of thyroxine is determined automatically by the ACE Clinical Chemistry System using a logarithmic calibration curve established with
	calibrators, which are provided separately.
	In the Ferritin Assay, serum ferritin, in the presence of anti-ferritin conjugated latex micorparticles, and a buffer promoting aggregation, initiates an antigen-antibody reaction, resulting in the agglutination of the latex microparticles. The agglutination is detected turbidometrically by an absorbance change measured at a wavelength of 592 nm. The magnitude of the absorbance change is proportional to the ferritin concentration in the sample.
Intended Use:	Indications for Use:
	The ACE Axcel Clinical Chemistry System is an automated, discrete, bench-top, random access analyzer that is intended for in vitro diagnostic use in the quantitative determination of constituents in blood and other fluids.
	ACE Hemoglobin A1c (HbA1c) Reagent is intended for the quantitative determination of hemoglobin A1c (µmol/L) and total hemoglobin (g/dL) in human EDTA whole blood for the calculation of percent hemoglobin A1c using the ACE Axcel Clinical Chemistry System. The test is intended for use in clinical laboratories or physician office laboratories to monitor long term blood glucose control in individuals with diabetes mellitus. For in vitro diagnostic use only.
	The ACE CEDIA T Uptake homogenous enzyme immunoassay is intended for the quantitative determination of unoccupied binding sites of thyroxine-binding proteins in serum using the ACE Axcel Clinical Chemistry System.
Measurements of triiodothyronine uptake are used in the diagnosis andtreatment of thyroid disorders. This test is intended for use in clinicallaboratories or physician office laboratories. For in vitro diagnostic use only.
The ACE T4 Reagent is intended for the quantitative determination of totalthyroxine (T4) concentration in serum using the ACE Axcel ClinicalChemistry System. Total thyroxine measurements are used in the diagnosis andtreatment of thyroid diseases. This test is intended for use in clinicallaboratories or physician office laboratories. For in vitro diagnostic use only.
The ACE Ferritin Reagent is intended for the quantitative determination offerritin concentration in serum using the ACE Axcel Clinical ChemistrySystem. Measurements of ferritin aid in the diagnosis of diseases affecting ironmetabolism, such as hemochromatosis (iron overload) and iron deficiencyanemia. This test is intended for use in clinical laboratories or physician officelaboratories. For in vitro diagnostic use only.
TechnologicalCharacteristics:	The following is a description of the major features of the ACE Axcel ClinicalChemistry System: System throughput is approximately 160 test results per hour for routine, single reagent chemistries. System throughput will be higher when the test workload includes ISE's. The instrument has a capacity of 40 reagent containers on board. A reagent cooling system maintains the reagents at 12°C during instrument operation. Reagent containers are identified by computer coded labels to simplify system operation. All reagents in the system must include an identification label on the container. Sample and reagent sensing notify the operator of a depleted condition during operation. The system performs analysis at a reaction temperature of 37°C. An electrolyte subsystem capable of measuring sodium, potassium and chloride concentrations is included. Primary draw tubes may be introduced one at a time into the system for closed tube sampling. Positive tube identification can be achieved with an optional barcode scanner. An aliquot volume sufficient for all tests ordered is transferred and stored and the closed tube is returned to the user. Sample cups are introduced to the system one at a time or by sample ring segment. Disposable cuvettes are loaded in bulk and then automatically injected as needed by a cuvette hopper system. The ACE Axcel Clinical Chemistry System optical system is capable of monitoring a maximum of 48 cuvettes at one time. The absorbance optical system is capable of absorbance measurements in a linear range of 0.0 to 2.0 absorbance units (at 0.67 cm pathlength).

{1}------------------------------------------------

{2}------------------------------------------------

{3}------------------------------------------------

{4}------------------------------------------------

Sixteen wavelengths are measured simultaneously using a photodiodearray.
The ACE HbA1c Reagent is composed of four reagent bottles (HemoglobinDenaturant, Total Hemoglobin Reagent, HbA1c Agglutinator Reagent andHbA1c Antibody Reagent). The Hemoglobin Denaturant contains: pepsin andbuffer (pH 2.4). The Total Hemoglobin Reagent contains: sodium hydroxide(pH 13) and Triton (Octylphenoxypolyethoxyethanol). The HbA1cagglutinator reagent contains: HbA1c hapten covalently attached to a polymer,bovine serum albumin and buffer (pH 2.0). The HbA1c Antibody Reagentcontains: HbA1c antibody (mouse) coupled particles, bovine serum albuminand buffer.
The ACE CEDIA T Uptake Reagent is composed of two dot-coded, emptyreagent bottles for the Enzyme Acceptor (EA) Reagent and the Enzyme Donor(ED) Reagent. These bottles are shrink-wrapped to the Roche DiagnosticsCobas CEDIA T Uptake kit. The EA Reagent contains enzyme acceptor(microbial), 0.111 g/L; phosphate buffer; buffer salts; stabilizers; preservative;detergent. The ED Reagent contains enzyme donor (microbial)-thyroxineconjugate, 0.44 mg/L; o-nitro-β-D-galactopyranoside, 3.27 g/L; phosphatebuffer; buffer salts; stabilizers; detergent; preservative.
The ACE T4 Reagent is composed of two reagent bottles (Antibody/SubstrateReagent and Enzyme Conjugate Reagent). The Antibody/Substrate Reagent(R1) contains: mouse monoclonal anti-thyroxine antibody, 8-anilino-1-naphthalene sulfonic acid, glucose-6-phosphate, nicotinamide adeninedinucleotide and Tris buffer. The Enzyme Conjugate Reagent (R2) contains:glucose-6-phosphate dehydrogenase labeled with thyroxine andTris buffer.
The ACE Ferritin Reagent is composed of two dot-coded, empty reagentbottles for the Ferritin Buffer and the Ferritin Antibody Reagent. The FerritinBuffer (R1) contains a glycine buffer. The Ferritin Antibody Reagent (R2)contains a suspension of latex particles sensitized with rabbit anti-humanferritin antibody. These bottles are shrink-wrapped to the Kamiya BiomedicalFerritin kit.

{5}------------------------------------------------

DEPARTMENT OF HEALTH & HUMAN SERVICES

Food and Drug Administration

Image /page/5/Picture/2 description: The image shows the seal of the U.S. Department of Health and Human Services. The seal features a stylized caduceus-like symbol with a bird-like figure. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES • USA" is arranged in a circular fashion around the symbol.

10903 New Hampshire Avenue Silver Spring, MD 20993

ALFA WASSERMANN Diagnostic Technologies, LLC c/o Hyman Katz, PhD 4 Henderson Drive West Caldwell, NJ 07006

Re: K113437

Trade Name: ACE Hemoglobin A1c (HbAlc) Reagent ACE CEDIA T Uptake Reagent ACE T4 Reagent ACE Ferritin Reagent

Regulation Number: 21 CFR §864.7470 Regulation Name: Glycosylated hemoglobin assay Regulatory Class: Class II Product Codes: LCP, KHQ, KLI, DBF Dated: July 30, 2012 Received: July 31, 2012

Dear Dr Katz:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Eederal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

ver Spring, MD 20993

AUG 6 2012

{6}------------------------------------------------

Page 2

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at (301) 796-5760. For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/Medical

Devices/Safety/ReportalProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance ...

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-5680 or at its Internet address http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm

Sincerely yours,

Steven H. Linder, Ph.D.

Couriney H. Lias, Ph.D. Director Division of Chemistry and Toxicology Devices Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health

Enclosure

{7}------------------------------------------------

Indications for Use

510(k) Number (if known): __ ヒハ 3 イフフ

Device Name: ACE Hemoglobin A1c (HbA1c) Reagent

Indications for Use:

ACE Hemoglobin A1c (HbA1c) Reagent is intended for the quantitative determination of hemoglobin Alc (umol/L) and total hemoglobin (g/dL) in human EDTA whole blood for the calculation of percent hemoglobin A1c using the ACE Axcel Clinical Chemistry System. The test is intended for use in clinical laboratories or physician office laboratories to monitor long term blood glucose control in individuals with diabetes mellitus. For in vitro diagnostic use only.

Prescription Use X (21 CFR Part 801 Subpart D) AND/OR

Over-The-Counter Use. (21 CFR Part 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE; CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

Division Sign-Off Office of In Vitro Diagnostic Device Evaluation and Safety

510(k) K113437

Page 1 of 3

{8}------------------------------------------------

Indications for Use

K113437 510(k) Number (if known):

Device Name: ACE CEDIA T Uptake Reagent

The ACE CEDIA T Uptake homogenous enzyme immunoassay is Indications for Use: intended for the quantitative determination of unoccupied binding sties of thyroxine-binding proteins in serum using the ACE Axcel Clinical Chemistry System. Measurements of triiodothyronine uptake are used in the diagnosis and treatment of thyroid disorders. This test is intended for use in clinical laboratories or physician office laboratories. For in vitro diagnostic use only.

Device Name: ACE T4 Reagent

Indications for Use: . The ACE T4 Reagent is intended for the quantitative determination of total thyroxine (T4) concentration in serum using the ACE Axcel Clinical Chemistry System. Total thyroxine measurements are used in the diagnosis and treatment of thyroid diseases. This test is intended for use in clinical laboratories or physician office laboratories. For in vitro diagnostic use only.

Prescription Use X (21 CFR Part 801 Subpart D) AND/OR

Over-The-Counter Use. (21 CFR Part 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE; CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

R. Chisholm

Division Sign-Off Office of In Vitro Diagnostic Device Evaluation and Safety

510(k) k 113437

Page 2 of 3

{9}------------------------------------------------

Indications for Use

K 113437

Device Name: ACE Ferritin Reagent

Indications for Use:

Prescription Use X (21 CFR Part 801 Subpart D) AND/OR

Over-The-Counter Use. (21 CFR Part 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE; CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

R. Charlie

Division Sign-Off Office of In Vitro Diagnostic Device Evaluation and Safety

510(k) k\13437

Page 3 of 3

Regulation Number and Section

§ 864.7470 Glycosylated hemoglobin assay.

(a)
Identification. A glycosylated hemoglobin assay is a device used to measure the glycosylated hemoglobins (A1a , A1b , and A1c ) in a patient's blood by a column chromatographic procedure. Measurement of glycosylated hemoglobin is used to assess the level of control of a patient's diabetes and to determine the proper insulin dosage for a patient. Elevated levels of glycosylated hemoglobin indicate uncontrolled diabetes in a patient.(b)
Classification. Class II (performance standards).